Zoetis Inc - Ordinary Shares - Class A

Strong Revenue Growth: Zoetis reported $2.2 billion in revenue for Q1 2025, achieving a 9% organic operational growth rate, driven by a 4% price increase and 5% volume growth. This reflects the strength of their diverse portfolio across both companion animals and livestock. The International segment led with an 11% organic growth rate, while the US segment grew at 6% on an organic operational basis.

Updated Guidance for 2025: The company maintains its full-year organic operational revenue growth guidance of 6% to 8%, and has updated its adjusted net income forecast to a range of $2.775 billion to $2.825 billion, reflecting an operational growth of 5% to 7%. The guidance incorporates expected impacts from enacted tariffs but does not account for potential future tariffs.

Opportunities in Companion Animal Segment: The companion animal portfolio showed strong growth, particularly through the Simparica franchise (19% growth) and key dermatology products, fuelled by a solid market presence and customer demand. With 20 million dogs still untreated for chronic conditions, there lies a substantial market opportunity ahead.